The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2020 | AML haplo-HSCT outcomes
Ali Bazarbachi, MD, PhD, American University of Beirut Medical Center, Beirut, Lebanon, discusses the results of a study evaluating the outcomes of acute myeloid leukemia (AML) patients receiving a haploidentical hematopoietic stem cell transplant (haplo-HSCT) with thiotepa/busulfan/fludarabine (TBF) conditioning and post-transplant cyclophosphamide versus a matched unrelated donor with fludarabine/busulfan conditioning. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
